IL33 and ovarian carcinoma: It was found that cisplatin promotes DNA transfer from ovarian cancer cells to CAFs, activates the CGAS-STING-IFNB1 pathway in CAFs, and promotes the release of IFNB1, and STING inhibitors sensitize platinum-based chemotherapy for ovarian cancer by inhibiting the CGAS-STING pathway in CAFs (Liu et al., 2024).IL-33 and culture supernatants derived from CAFs, but not from normal ovarian fibroblasts, lead to higher expression of the M2 macrophage marker genes in human blood monocytes, which promotes macrophage polarization toward M2 and tumor progression (Feng et al., 2022a).